Suppr超能文献

内在和外在因素对抗体药物偶联物(ADCs)药代动力学的影响。

Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody-Drug Conjugates (ADCs).

作者信息

Mahmood Iftekhar

机构信息

Mahmood Clinical Pharmacology Consultancy, LLC., Rockville, MD 20850, USA.

出版信息

Antibodies (Basel). 2021 Oct 15;10(4):40. doi: 10.3390/antib10040040.

Abstract

Antibody-drug conjugates (ADCs) are complex molecules wherein a monoclonal antibody is linked to a biologically active drug (a small molecule), forming a conjugate. Initially, most of the ADCs were developed and are being developed for the treatment of cancer; however, with time, it has been realized that ADCs can also be developed to manage or cure other diseases. Pharmacokinetics (PK) plays an important role in modern-day drug development and the knowledge of PK is crucial in designing a safe and efficacious dose to treat a wide variety of diseases. There are several factors that can alter the PK of a drug; as a result, one has to adjust the dose in a patient population. These factors can be termed 'intrinsic' or 'extrinsic'. For small molecules, the impact of both intrinsic and extrinsic factors is well established. The impact of age, gender, disease states such as renal and hepatic impairment, drug-drug interaction, food, and in many cases alcohol on the PK of small molecules are well known. On the other hand, for macromolecules, the impact of these factors is not well established. Since the ADCs are a combination product of a monoclonal antibody linked to a small molecule, both the small molecule and the monoclonal antibody of the ADCs may be subjected to many intrinsic and extrinsic factors. This review summarizes the impact of intrinsic and extrinsic factors on the PK of ADCs and the payloads.

摘要

抗体药物偶联物(ADCs)是复杂的分子,其中单克隆抗体与生物活性药物(小分子)相连,形成偶联物。最初,大多数ADC是为癌症治疗而开发的,并且仍在开发中;然而,随着时间的推移,人们意识到ADC也可用于治疗或治愈其他疾病。药代动力学(PK)在现代药物开发中起着重要作用,PK知识对于设计安全有效的剂量以治疗各种疾病至关重要。有几个因素可以改变药物的PK;因此,必须在患者群体中调整剂量。这些因素可分为“内在”或“外在”因素。对于小分子,内在和外在因素的影响已得到充分证实。年龄、性别、疾病状态(如肾和肝功能损害)、药物相互作用、食物以及在许多情况下酒精对小分子PK的影响是众所周知的。另一方面,对于大分子,这些因素的影响尚未得到充分证实。由于ADC是与小分子相连的单克隆抗体的组合产品,ADC的小分子和单克隆抗体都可能受到许多内在和外在因素的影响。本综述总结了内在和外在因素对ADC及其有效载荷PK的影响。

相似文献

3
Clinical Pharmacology of Antibody-Drug Conjugates.抗体药物偶联物的临床药理学
Antibodies (Basel). 2021 May 21;10(2):20. doi: 10.3390/antib10020020.
4
Introduction to Antibody-Drug Conjugates.抗体药物偶联物简介。
Antibodies (Basel). 2021 Oct 27;10(4):42. doi: 10.3390/antib10040042.

本文引用的文献

1
Clinical Pharmacology of Antibody-Drug Conjugates.抗体药物偶联物的临床药理学
Antibodies (Basel). 2021 May 21;10(2):20. doi: 10.3390/antib10020020.
2
Does Hepatic Impairment Affect the Exposure of Monoclonal Antibodies?肝脏损伤对单克隆抗体的暴露有影响吗?
Clin Pharmacol Ther. 2020 May;107(5):1256-1262. doi: 10.1002/cpt.1765. Epub 2020 Jan 28.
8
Antibody-drug conjugates for non-oncological indications.用于非肿瘤学适应症的抗体药物偶联物。
Expert Opin Biol Ther. 2016;16(5):591-3. doi: 10.1517/14712598.2016.1161753. Epub 2016 Mar 21.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验